Cited by 5,761Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Open access

Sandler, Alan, Gray, Robert, Perry, Michael C., Brahmer, Julie, Schiller, Joan H., Dowlati, Afshin, Lilenbaum, Rogerio, Johnson, David H.·2006·New England Journal of Medicine

DOI 10.1056/nejmoa061884

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. METHODS: Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival. RESULTS: The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. CONCLUSIONS: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Integrity signals

Registry

Crossref · 10.1056/nejmoa061884

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citation
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,985

Show all 24 references

Research works printed but not linked: 4

Brown LF, 1993, Cancer Res, 53, 4727
Kabbinavar FF, 1995, Proc Am Assoc Cancer Res, 36, 488
Borgstrom P, 1999, Anticancer Res, 19, 4203
Miller KD, 2005, Breast Cancer Res Treat, 94, S6

Sorted by citations

Items 301–400 of 1,018

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Reslan, H. B., Ho, C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 214
Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis
Lee, S. H., Jeong, D., Han, Y., & Baek, M. J. (2015) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2015.89.1.1 · Cited by 215
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Aebi, S. P., Gelber, S. I., Anderson, S., Láng, I., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Cañada, J. M. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70589-8 · Cited by 213
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
Ramlau, R., Quoix, É., Rolski, J., Pless, M., Léna, H., Lévy, E., Krzakowski, M. J., Hess, D., Tartour, É., Chenard, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b4f · Cited by 209
Molecular biology of lung cancer: Clinical implications
Fong, K. M., & Minna, J. D. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00062-5 · Cited by 211
CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis
Jiang, T.-X., Zhuang, J., Duan, H., Luo, Y., Zeng, Q., Fan, K., Yan, H., Lü, D., Ye, Z., Hao, J., et al. (2012) · Blood · doi:10.1182/blood-2012-01-406108 · Cited by 216
Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer
Zhao, Y., Zeng, D., Socinski, M. A., & Kosorok, M. R. (2011) · Biometrics · doi:10.1111/j.1541-0420.2011.01572.x · Cited by 208
ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Johnson, B. E., Kabbinavar, F. F., Fehrenbacher, L., Hainsworth, J. D., Kasubhai, S. M., Kressel, B. R., Lin, C.-Y., Marsland, T., Patel, T., Polikoff, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3983 · Cited by 212
Combinations of Bevacizumab With Cancer Immunotherapy
Chen, D. S., & Hurwitz, H. I. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000327 · Cited by 208
Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010
Okami, J., Shintani, Y., Okumura, M., Ito, H., Ohtsuka, T., Toyooka, S., Mori, T., WATANABE, S.-I. I., Date, H., Yokoi, K., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.002 · Cited by 212
Dual-targeted Contrast Agent for US Assessment of Tumor Angiogenesis in Vivo
Willmann, J. K., Lutz, A. M., Paulmurugan, R., Patel, M. R., Chu, P., Rosenberg, J., & Gambhir, S. S. (2008) · Radiology · doi:10.1148/radiol.2483072231 · Cited by 206
Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity
Ferri, N., Siegl, P. K. S., Corsini, A., Herrmann, J., Lerman, A., & Benghozi, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.005 · Cited by 214
Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
Tugues, S., Koch, S., Gualandi, L., Li, X., & Claesson, L. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.004 · Cited by 209
Sex differences in lung cancer susceptibility: A review
Kiyohara, C., & Ohno, Y. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.10.002 · Cited by 206
The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path ForwardPreprint
Kieran, M. W., Kalluri, R., & Cho, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006593 · Cited by 212
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
Kimura, H., Suminoe, M., Kasahara, K., Sone, T., Araya, T., Tamori, S., Koizumi, F., Nishio, K., Miyamoto, K., Fujimura, M., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603949 · Cited by 200
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
Drilon, A. E. D. C., Rekhtman, N., Ladanyi, M., & Paik, P. K. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70291-7 · Cited by 205
Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
Blumenschein, G. R., Gatzemeier, U., Fossella, F. V., Stewart, D. J., Cupit, L., Cihon, F., O'Leary, J., & Reck, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0541 · Cited by 205
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C., Yang, J. C., & Yang, P. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 212
FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
Heist, R. S., Mino-Kenudson, M. A., Sequist, L. V. D., Tammireddy, S., Morrissey, L., Christiani, D. C., Engelman, J. A., & Iafrate, A. J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826aed28 · Cited by 204
Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
Oldham, R. K., & Dillman, R. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7438 · Cited by 207
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
Niho, S., Kunitoh, H., Nokihara, H., Horai, T., Ichinose, Y., Hida, T., Yamamoto, N., Kawahara, M., Shinkai, T., Nakagawa, K., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.005 · Cited by 204
Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
Win, T., Miles, K. A., Janes, S. M., Ganeshan, B., Shastry, M., Endozo, R., Meagher, M., Shortman, R. I., Wan, S., Kayani, I. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1307 · Cited by 203
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00838-y · Cited by 197
New molecularly targeted therapies for lung cancer
Sun, S., Schiller, J. H., Spinola, M., & Minna, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31809 · Cited by 202
Self-citation
Roles for VEGF in the adult
Maharaj, A. S. R., & D'Amore, P. A. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.03.004 · Cited by 202
Cancer metastasis as a therapeutic target
Sleeman, J. P., & Steeg, P. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.039 · Cited by 198
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kim, K. B., Sosman, J. A., Fruehauf, J. P., Linette, G. P., Markovic, S. N., McDermott, D. F., Weber, J. S., Nguyen, H. T., Cheverton, P., Chen, D. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.6270 · Cited by 196
Vorinostat in solid and hematologic malignancies
Siegel, D. S. D., Hussein, M. A., Belani, C. P., Robert, F., Galanis, E., Richon, V. M., Garcia-Vargas, J. E., Sanz-Rodrı́guez, C., & Rizvi, S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-31 · Cited by 196
Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20
Arnold, A., Seymour, L., Smylie, M., Ding, K., Ung, Y., Findlay, B., Lee, C. W., Djurfeldt, M., Whitehead, M., Ellis, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3083 · Cited by 196
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D. H., Alam, Y., Kreisman, H., Graze, P. R., Maher, J. F., Ross, H. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0856 · Cited by 195
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
Minguet, J., Smith, K. H., & Bramlage, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29915 · Cited by 198
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
Chinot, O. L., Rouge, T. D. L. M., Moore, N., Zeaiter, A. H., Das, A., PHILLIPS, H. S., Modrusan, Z. D., & Cloughesy, T. F. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0007-3 · Cited by 195
Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects
Takes, R. P., Rinaldo, A., Silver, C. E., Haigentz, M., Woolgar, J. A., Triantafyllou, A. G., Mondin, V., Paccagnella, D., de Bree, R., Shaha, A. R., et al. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.03.013 · Cited by 199
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman, M., Watson, D., Wang, X.-F., Morrison, C., Kratzke, R., Jewell, S., Hodgson, L., Mauer, A., Gajra, A., Masters, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8081 · Cited by 200
Immunomodulatory Activity of VEGF in Cancer
Lapeyre-Prost, A., Terme, M., Pernot, S., Pointet, A., Voron, T., Tartour, É., & Taı̈eb, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 203
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
Sugawara, S., Lee, J.-S., Kang, J., Kim, H. R., Inui, N., Hida, T., Lee, K. H., Yoshida, T., Tanaka, H., Yang, C., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.004 · Cited by 195
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Hegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., & Chen, D. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2535 · Cited by 193
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
Ramalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193
Targeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala‐Dilke, K., & Bergers, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 216
Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis
Zhan, P., Wang, J., Lv, X.-J., Wang, Q., Qiu, L., Lin, X.-Q., Yu, L.-K., & Song, Y. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a97e31 · Cited by 191
Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Minniti, G. C., Muni, R., Lanzetta, G., Marchetti, P., & Enrici, R. M. (2009) · PubMed · Cited by 191
First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review
Goffin, J. R., Lacchetti, C., Ellis, P. M., Ung, Y., & Evans, W. K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c6f035 · Cited by 191
Genetic Changes in Squamous Cell Lung Cancer: A Review
Heist, R. S., Sequist, L. V. D., & Engelman, J. A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824cc334 · Cited by 197
A Structured Exercise Program for Patients with Advanced Non-small Cell Lung Cancer
Temel, J. S., Greer, J. A., Goldberg, S. B., Vogel, P. D., Sullivan, M., Pirl, W. F., Lynch, T. J., Christiani, D. C., & Smith, M. R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819d18e5 · Cited by 190
Signaling Pathways Governing Tumor Angiogenesis
Sakurai, T., & Kudo, M. (2011) · Oncology · doi:10.1159/000333256 · Cited by 193
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
Hahn, N. M., Stadler, W. M., Zon, R. T., Waterhouse, D. M., Picus, J., Nattam, S. R., Johnson, C. S., Perkins, S. M., Waddell, M. J., & Sweeney, C. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6067 · Cited by 190
Disorders of Vascular Permeability
Park‐Windhol, C., & D'Amore, P. A. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044506 · Cited by 194
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Nan, X., Xie, C., Yu, X., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20095 · Cited by 203
Treatment of Stage IV Non-small Cell Lung Cancer
Socinski, M. A., Evans, T. L., Gettinger, S. N., Hensing, T. A., Sequist, L. V. D., Ireland, B. K., & Stinchcombe, T. E. (2013) · CHEST Journal · doi:10.1378/chest.12-2361 · Cited by 206
VEGF inhibition: insights from preclinical and clinical studies
Crawford, Y., & Ferrara, N. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0675-8 · Cited by 192
VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma
Maharaj, A. S. R., Walshe, T. E., Saint‐Geniez, M., Venkatesha, S., Maldonado, A. E., Himes, N. C., Matharu, K., Karumanchi, S. A., & D'Amore, P. A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072041 · Cited by 193
Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
D’Addario, G., & Felip, E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp132 · Cited by 187
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C. S., Tan, D. S. W., Lee, D., Misch, D., Garralda, E., Kim, D.-W., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.002 · Cited by 186
Intricacies of Bevacizumab-Induced Toxicities and Their Management
Ussery, S. M. G., & Shah, S. R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l426 · Cited by 192
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Lambrechts, D., Claes, B., Delmar, P., Reumers, J., Mazzone, M., Yesilyurt, B. T., Devlieger, R., Verslype, C., Tejpar, S., Wildiers, H. P. M. W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70231-0 · Cited by 187
Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
Shah, M. A., Jhawer, M. P., Ilson, D. H., Lefkowitz, R. A., Robinson, E. A. E., Capanu, M., & Kelsen, D. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0770 · Cited by 186
Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
Hapani, S., Sher, A. F., Chu, D. T. W., & Wu, S. (2010) · Oncology · doi:10.1159/000314980 · Cited by 185
Determining the optimal dose in the development of anticancer agents
Mathijssen, R. H. J., Sparreboom, A., & Verweij, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.40 · Cited by 184
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
Scagliotti, G. V., Vynnychenko, I. O., Park, K., Ichinose, Y., Kubota, K., Blackhall, F. H., Pirker, R., Galiulin, R., Ciuleanu, T., Sydorenko, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4987 · Cited by 184
Novel therapeutic targets on the horizon for lung cancer
Tan, W.-L., Jain, A., Takano, A. M., Newell, E. W., Iyer, N. G., Lim, W., Tan, E.-H., Zhai, W., Hillmer, A. M., Tam, W. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30123-1 · Cited by 185
The VEGF family in cancer and antibody-based strategies for their inhibition
Sullivan, L. A., & Brekken, R. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11360 · Cited by 184
Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST
Nishino, M., Jagannathan, J. P., Krajewski, K. M., O'Regan, K. N., Hatabu, H., Shapiro, G. I., & Ramaiya, N. H. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.7483 · Cited by 179
Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy
Rapisarda, A., & Melillo, G. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-386503-8.00006-5 · Cited by 186
A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome
Mooney, C. J., Nagaiah, G., Fu, P., Wasman, J. K., Cooney, M. M., Savvides, P. S., Bokar, J. A., Dowlati, A., Wang, D., Agarwala, S. S., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0321 · Cited by 180
Self-citation
The role of blood platelets in tumor angiogenesis
Sabrkhany, S., Griffioen, A. W., & Egbrink, M. G. A. O. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.12.001 · Cited by 181
The Biology of Brain Metastasis
Fidler, I. J. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000126 · Cited by 181
Clinicopathologic Features of Advanced Squamous NSCLC
Socinski, M. A., Obasaju, C. K., Gandara, D. R., Hirsch, F. R., Bonomi, P., Bunn, P. A., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.024 · Cited by 186
Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment – New Findings and Future Perspectives
Nagl, L., Horvath, L., Pircher, A., & Wolf, D. G. F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00766 · Cited by 189
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
Badgwell, B. D., Camp, E. R., Feig, B. W., Wolff, R. A., Eng, C., Ellis, L. M., & Cormier, J. N. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm508 · Cited by 180
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
Bevacizumab: A Review of Its Use in Advanced Cancer
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0302-9 · Cited by 186
Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer
Patel, J. D., Hensing, T. A., RADEMAKER, A. W., Hart, E. M., Blum, M. G., Milton, D. T., & Bonomi, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8181 · Cited by 178
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer
Chiappori, A., Kolevska, T., Spigel, D. R., Hager, S. J., Rarick, M. U., Gadgeel, S. M., Blais, N., von Pawel, J., Hart, L., Reck, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu550 · Cited by 180
Self-citation
Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
Stockler, M. R., Hilpert, F., Friedlander, M. L., King, M. T., Wenzel, L. B., Lee, C. K., Joly, F., de Gregorio, N., Arranz, J. Á., Mirza, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4240 · Cited by 177
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 178
Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
Kimura, M., Naito, T., Kenmotsu, H., Taira, T., Wakuda, K., Oyakawa, T., Hisamatsu, Y., Tokito, T., Imai, H., Akamatsu, H., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2534-3 · Cited by 176
Role of Vascular Endothelial Growth Factor (VEGF) in Human Embryo Implantation: Clinical Implications
Guo, X. W., Yi, H. L., Li, T. C., Wang, Y., Wang, H., & Chen, X. (2021) · Biomolecules · doi:10.3390/biom11020253 · Cited by 188
Epigenetics of lung cancer
Langevin, S. M., Kratzke, R. A., & Kelsey, K. T. (2014) · Translational research · doi:10.1016/j.trsl.2014.03.001 · Cited by 174
Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
Maitland, M. L., Kasza, K., Karrison, T. G., Moshier, K., Sit, L., Black, H. R., Undevia, S. D., Stadler, W. M., Elliott, W. J., & Ratain, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0058 · Cited by 176
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Desjardins, A., Reardon, D. A., Herndon, J. E., Marcello, J. E., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., Bailey, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0260 · Cited by 173
Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
Schiller, J. H., Larson, T. G., Ou, S.-H. I., Limentani, S. A., Sandler, A. B., Vokes, E. E., Kim, S., Liau, K., Bycott, P. W., Olszanski, A. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8355 · Cited by 173
Self-citation
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Majem, M., Juan, Ó., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García‐Campelo, R., García, Y. G., Guirado, M., & Provencio, M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1978-1 · Cited by 178
Nanotechnology in the diagnosis and treatment of lung cancer
Cryer, A. M., & Thorley, A. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.010 · Cited by 177
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Jänne, P. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1455 · Cited by 171
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0274 · Cited by 171
Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications
Rudin, C. M., Ávila-Tang, É., Harris, C. C., Herman, J. G., Hirsch, F. R., Pao, W. J., Schwartz, A. G., Vähäkangas, K., & Samet, J. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0377 · Cited by 175
Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor
Park, M. S., Ravi, V., & Araujo, D. M. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833aaad4 · Cited by 171
Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
Shojaei, F., & Ferrara, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0925 · Cited by 172
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A. A., Leighl, N. B., Aisner, S. C., Rothman, J. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30691-5 · Cited by 171
Self-citation
Renal Effects of Anti-angiogenesis Therapy: Update for the Internist
Gurevich, F., & Perazella, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.11.025 · Cited by 170
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells
Wilcox, R. A., Wada, D. A., Ziesmer, S. C., Elsawa, S. F., Comfere, N. I., Dietz, A. B., Novak, A. J., Witzig, T. E., Feldman, A. L., Pittelkow, M. R., et al. (2009) · Blood · doi:10.1182/blood-2009-05-220111 · Cited by 170
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications
Kellar, A., Egan, C., & Morris, D. G. (2015) · BioMed Research International · doi:10.1155/2015/621324 · Cited by 179
A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
Rosen, L. S., Hurwitz, H. I., Wong, M. K., Goldman, J. W., Mendelson, D. S., Figg, W. D., Spencer, S. D., Adams, B. J., Alvarez, D., Seon, B. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0098 · Cited by 170
Epigenetics in lung cancer diagnosis and therapy
Mehta, A., Dobersch, S., Romero‐Olmedo, A. J., & Barreto, G. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9563-3 · Cited by 171
Treatment of Non-small Cell Lung Cancer, Stage IV
Socinski, M. A., Crowell, R. E., Hensing, T., Langer, C. J., Lilenbaum, R., Sandler, A. B., & Morris, D. (2007) · CHEST Journal · doi:10.1378/chest.07-1381 · Cited by 169
Self-citation
Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
Gandara, D. R., Hammerman, P. S., Sos, M. L., Lara, P. N., & Hirsch, F. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3039 · Cited by 168
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Linger, R. M. A., Keating, A. K., Earp, H. S., & Graham, D. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.515980 · Cited by 171
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer
Sandler, A. B., Yi, J., Dahlberg, S. E., Kolb, M. M., Wang, L. E., Hambleton, J., Schiller, J. H., & Johnson, D. H. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181da36f4 · Cited by 168
Self-citation
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
Greco, F. A., Bonomi, P., Crawford, J., Kelly, K. L., Oh, Y. W., Halpern, W., Lo, L., Gallant, G., & Klein, J. L. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168

Authors: Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H.
Affiliations: Vanderbilt University (US)
Dana-Farber Cancer Institute (US)
University of Missouri (US)
Johns Hopkins University (US)
University of Wisconsin–Madison (US)
University Hospitals of Cleveland (US)
ORCID: Sandler, Alan
Gray, Robert
Brahmer, Julie
Schiller, Joan H.
Dowlati, Afshin
Johnson, David H.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2006-12-14
Volume: 355
Issue: 24
Pages: 2542-2550
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa061884
OpenAlex: W2145835533
Cited by: 5,761
References: 24
Citations by year: 2026: 49 · 2025: 71 · 2024: 112 · 2023: 135 · 2022: 177 · 2021: 183 · 2020: 180 · 2019: 227 · 2018: 257 · 2017: 278 · 2016: 321 · 2015: 389 · 2014: 400 · 2013: 461 · 2012: 513
FWCI: 299.17
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (U10CA066636, CA-23318, CA49957, U10CA016116, CA66636, U10CA012046, U10CA014548, CA-16116, CA14548, U10CA031946, CA21076, U10CA049957, U10CA021076, U10CA023318, U10CA021115, CA 21115, CA-31946, CA12046)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: non-small cell lung cancer, bevacizumab, paclitaxel, carboplatin, combination chemotherapy, vascular endothelial growth factor inhibition, overall survival, progression-free survival, pulmonary hemorrhage
MeSH terms: Bevacizumab, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Carboplatin, Paclitaxel, Disease-Free Survival, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks